Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The main objective of the trial is to compare the anti-inflammatory effects of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed) versus a fixed dose treatment that includes both Symbicort Turbuhaler (320/9 µg/inhalation b.i.d.) and Pulmicort® Turbuhaler (400 µg/dose b.i.d.) plus Terbutaline Turbuhaler (0.4 mg/inhalation as-needed) on the immunopathology and remodelling of the asthmatic lung.
Critère d'inclusion
- This is a Phase IIIB trial to be conducted in adlut asthmatic patients